Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Co-Diagnostics
CODX
Co-Diagnostics
Revenue Drops And Regulatory Delays Will Spark A Cautious Rebound
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
18 Aug 25
Updated
18 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$1.00
68.0% undervalued
intrinsic discount
18 Aug
US$0.32
Loading
1Y
-81.4%
7D
26.7%
Author's Valuation
US$1.0
68.0% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$1.0
68.0% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-193m
105m
2014
2017
2020
2023
2025
2026
2028
Revenue US$65.5m
Earnings US$8.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
75.78%
Medical Equipment revenue growth rate
0.44%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.84%
Calculation
US$8.13m
Earnings '28
x
8.12x
PE Ratio '28
=
US$66.02m
Market Cap '28
US$66.02m
Market Cap '28
/
52.65m
No. shares '28
=
US$1.25
Share Price '28
US$1.25
Share Price '28
Discounted to 2025 @ 7.84% p.a.
=
US$1.00
Fair Value '25
